DAKLINZA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by E.r. Squibb & Sons, L.l.c.. The primary component is Daclatasvir Dihydrochloride.
| Product ID | 0003-0215_780ae42b-9b05-4a02-9529-5e45dbb460f6 |
| NDC | 0003-0215 |
| Product Type | Human Prescription Drug |
| Proprietary Name | DAKLINZA |
| Generic Name | Daclatasvir |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2015-07-27 |
| Marketing End Date | 2019-12-31 |
| Marketing Category | NDA / NDA |
| Application Number | NDA206843 |
| Labeler Name | E.R. Squibb & Sons, L.L.C. |
| Substance Name | DACLATASVIR DIHYDROCHLORIDE |
| Active Ingredient Strength | 60 mg/1 |
| Pharm Classes | Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Marketing Start Date | 2015-07-27 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA206843 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2015-07-27 |
| Marketing End Date | 2019-12-31 |
| Ingredient | Strength |
|---|---|
| DACLATASVIR DIHYDROCHLORIDE | 60 mg/1 |
| SPL SET ID: | 9803a6ff-8a3e-4c64-b3d0-7825c7123bf2 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0003-0011 | DAKLINZA | daclatasvir |
| 0003-0213 | DAKLINZA | daclatasvir |
| 0003-0215 | DAKLINZA | daclatasvir |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() DAKLINZA 85871477 5171750 Live/Registered |
Bristol-Myers Squibb Company 2013-03-08 |